European Journal of Case Reports in Internal Medicine, 2021 Graves' disease is the most frequent cause of hyperthyroidism in young women. This auto-immune disease is due to the production of class 1 IgG stimulating the TSH receptor.
Guillaume Pierman +2 more
semanticscholar +1 more source
Archives of Endocrinology and Metabolism, 2020 Objective Graves’ disease (GD) is the main cause of hyperthyroidism among adults. It is an autoimmune condition classically marked by the Merserburg Triad (goiter, thyrotoxicosis, and orbitopathy), but the change in presentation of GD over time has ...
Wanesa Pinto +4 more
doaj +1 more source
Minimal change disease associated with Graves’ disease and methimazole use
Revista Colombiana de Nefrología, 2022 Introduction. Graves' disease causes kidney injury through multiple mechanisms, including the treatment for this condition. Nephrotic syndrome due to minimal change disease (MCD) is an unusual form of such kidney injury; the association between ...
Andrés Fernando Rodríguez-Gutiérrez +1 more
doaj +1 more source
Prevalence of thyroid eye disease in Graves’ disease: A meta‐analysis and systematic review
Clinical Endocrinology, 2020 Thyroid eye disease (TED) is a debilitating condition that frequently manifests in patients suffering from Graves’ disease (GD). This study aims to analyse the prevalence of TED among GD patients, with a focus on geographical region‐specific rates.
Y. Chin +7 more
semanticscholar +1 more source
Updates in the Management of Graves Disease in Children
The Ewha Medical Journal, 2023 Graves disease (GD) is the primary cause of hyperthyroidism in children. The standard management options—namely, antithyroid drugs (ATD), radioactive iodine, and surgery—have not changed for many years.
Yun Jeong Lee
doaj +1 more source
Graves’ disease with spontaneous resolution following ocrelizumab in primary progressive multiple sclerosis [PDF]
, 2021 Objectives. Immune reconstitution therapies (IRT), which include antibody-based cell-depleting therapies targeting CD52+ (alemtuzumab) or CD20+ (rituximab, ocrelizumab) leukocytes, are approved for the treatment of multiple sclerosis.
Cardoso, Helena +3 more
core +1 more source
Management of patients with Graves' disease and orbital involvement: role of spectral domain optical coherence tomography [PDF]
, 2018 PURPOSE: To investigate the role of choroidal thickness evaluation with spectral domain optical coherence tomography (SDOCT) and enhanced depth imaging (EDI) technique in the management of patients with Graves' disease and orbitopathy (GO).
Bruscolini, A +7 more
core +1 more source
Radioiodine treatment for graves’ disease: a 10-year Australian cohort study
BMC Endocrine Disorders, 2018 Background Radioactive iodine (I131) is a common definitive treatment for Graves’ Disease. Potential complications include worsening, or new development of Graves’ eye disease and development of a radiation thyroiditis.
Erin Fanning +2 more
doaj +1 more source
Antigen receptor variable region repertoires expressed by T cells infiltrating thyroid, retroorbital, and pretibial tissue in Graves' disease [PDF]
, 1996 To date, it has remained unclear whether T cells infiltrating thyroid, retroorbital, and pretibial tissue of patients with Graves' ophthalmopathy and pretibial dermopathy represent a primary immune response that is directed against certain antigenic ...
Heufelder, Armin E. +2 more
core +1 more source
Rituximab in the treatment of Graves’ orbitopathy: latest updates and perspectives
Endocrine Connections, 2022 Graves’ orbitopathy (GO) is a potentially sight-threatening and disfiguring, extrathyroidal manifestation of Graves’ disease. It often impairs patients’ qu ality of life, causing severe social and psychological sequelae.
Jakub Supronik +3 more
doaj +1 more source